Is Shattuck Labs, Inc. overvalued or undervalued?

As of 9 November 2023, Shattuck Labs, Inc. has moved from a grade of "does not qualify" to "risky," indicating a significant change in its valuation outlook. The company is currently assessed as overvalued given its negative financial metrics, including a price-to-book value of 0.81 and an EV to EBITDA ratio of 0.08, which are concerning for a company in this sector. Additionally, the return on equity (ROE) stands at a staggering -104.36%, highlighting the challenges it faces in generating profits.
In comparison to its peers, Shattuck Labs' valuation metrics are less favorable. For instance, Avrobio, Inc. has a P/E ratio of -6.6206 and an EV to EBITDA of -1.2033, while HCW Biologics Inc. shows a P/E of -0.9336 and an EV to EBITDA of -2.2204, both indicating struggles similar to Shattuck Labs. The company's stock has underperformed significantly, with a year-to-date return of -16.53% compared to a 2.44% gain in the S&P 500, further reinforcing the notion that it is currently overvalued in the market.